Out of Zion Award Program
Total 2020 Award: $62,500
2020 Recipient: St. Baldrick’s Scholar/Hope4ATRT Award
Award Amount: $50,000
St. Baldrick's Foundation (SBF) and Hope4ATRT will fund a joint pediatric cancer research grant that is evaluated to be scientifically viable by both foundations. Funding from Hope4ATRT is restricted to research focused on ATRT or work that can benefit ATRT patients. The funds raised will provide much needed support for investigation of brain tumor research. Specifically of interest to HopeATRT is central nervous system atypical teratoid/rhabdoid tumor (AT/RT).
Stand Up To Cancer-St. Baldrick's Foundation Dream Team has been selected as the specific project for this award. More details can be found in this Press Release.
2020 Recipient: Children’s Hospital of Philadelphia (CHOP) and Children’s Brain Tumor Network (CBTN)
Award Amount: $12,500
This fund is established to support the Whole Genome Sequencing (WGS) of the Children’s Brain Tumor Network (CBTN) Atypical Teratoid Rhabdoid Tumors (ATRT). There are currently 11 ATRT tumors that need WGS. These funds are estimated to cover 50% of the total cost to sequence all 11 tumors.
These efforts may include the full range of research, from basic laboratory studies to clinical trials, including multi-center trials.
Total 2019 Award: $25,000
2019 Recipient: ATRT Translational Research Program
Award Amount: $25,000
In collaboration with the Hope4ATRT Foundation, the ATRT Translational Research Program, within Beat Childhood Cancer, focuses on identifying children with ATRT to support them through clinical treatment trials, and provide resources for the affected children and their caregivers. The Out of Zion Award from the Hope4ATRT Foundation offers assistance for children with ATRT to enroll in The Signature Study: Molecular Analysis of Pediatric Tumors with Establishment of Tumor Models in an Exploratory Biology Study. This study allows the tumor to undergo complete genomic analysis to better understand the biology of each child’s tumor by identifying the mutations or pathways active in driving the tumor. In addition, the tumor cells are grown in culture and xenograft models for high throughput drug screening.